LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software
SINGAPORE--September 13, 2023--Us2.ai, a Singapore-based MedTech firm, has partnered with Duke University to co-develop and commercialize AI tools for echocardiography, to enable earlier detection, improved diagnosis and more efficient management of heart disease.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.